Literature DB >> 9440707

Spatial relationship of the C-terminal domains of dystrophin and beta-dystroglycan in cardiac muscle support a direct molecular interaction at the plasma membrane interface.

S Stevenson1, S Rothery, M J Cullen, N J Severs.   

Abstract

Dystrophin and beta-dystroglycan are components of a complex of at least nine proteins (the dystrophin-glycoprotein complex) that physically link the membrane cytoskeleton in skeletal and cardiac muscle, through the plasma membrane, to the extracellular matrix. Mutations in the dystrophin gene, which result in an absence or a quantitative or qualitative alteration of dystrophin, cause a subset of familial dilated cardiomyopathies as well as Duchenne and Becker muscular dystrophy. Biochemical studies on isolated skeletal muscle molecules indicate that dystrophin is bound to the glycoprotein complex via beta-dystroglycan, with the C-terminus of beta-dystroglycan binding to the cysteine-rich domain and first half of the C-terminal domain of dystrophin. Ultrastructural labeling has demonstrated a close spatial relationship between dystrophin and beta-dystroglycan in intact skeletal muscle, but no previous ultrastructural labeling studies have examined the dystrophin/beta-dystroglycan interaction in cardiac muscle. In the present study, we have applied complementary immunoconfocal microscopy and double immunogold fracture-label, a freeze-fracture cytochemical technique that allows high-resolution visualization of labeled membrane components in thin section and in platinum-carbon replicas, to investigate the spatial relationship between dystrophin and beta-dystroglycan in rat cardiac muscle. When immunogold probes of two different sizes for the two proteins were used, "doublets" representing side-by-side antibody labeling were demonstrated in en face views at the level of the plasma membrane. The results support the conclusions that dystrophin and beta-dystroglycan directly interact at the cytoplasmic face of the rat cardiac muscle plasma membrane.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9440707     DOI: 10.1161/01.res.82.1.82

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  6 in total

1.  Utrophin and dystrophin-associated glycoproteins in normal and dystrophin deficient cardiac muscle.

Authors:  F Rivier; A Robert; M Royuela; G Hugon; A Bonet-Kerrache; D Mornet
Journal:  J Muscle Res Cell Motil       Date:  1999-04       Impact factor: 2.698

2.  Dystrophin and the cardiomyocyte membrane cytoskeleton in the healthy and failing heart.

Authors:  R R Kaprielian; N J Severs
Journal:  Heart Fail Rev       Date:  2000-10       Impact factor: 4.214

3.  An ischemic beta-dystroglycan (betaDG) degradation product: correlation with irreversible injury in adult rabbit cardiomyocytes.

Authors:  Stephen C Armstrong; Carole A Latham; Charles E Ganote
Journal:  Mol Cell Biochem       Date:  2003-01       Impact factor: 3.396

4.  Microdystrophin gene therapy of cardiomyopathy restores dystrophin-glycoprotein complex and improves sarcolemma integrity in the mdx mouse heart.

Authors:  Yongping Yue; Zhenbo Li; Scott Q Harper; Robin L Davisson; Jeffrey S Chamberlain; Dongsheng Duan
Journal:  Circulation       Date:  2003-09-02       Impact factor: 29.690

5.  Assessing the reproducibility of labelled antibody binding in quantitative multiplexed immuno-mass spectrometry imaging.

Authors:  Jonathan Wanagat; David P Bishop; Monique G Mello; Mika T Westerhausen; Prashina Singh; Philip A Doble
Journal:  Anal Bioanal Chem       Date:  2021-07-25       Impact factor: 4.478

6.  Recent advances in freeze-fracture electron microscopy: the replica immunolabeling technique.

Authors:  Horst Robenek; Nicholas J Severs
Journal:  Biol Proced Online       Date:  2008-01-28       Impact factor: 3.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.